Search Results
Jan 22, 2026, 05:29 ET Chandigarh University Launches India's First 'AI Fest - 2026'; Registration Portal Launched
The unveiling of the AI Fest was done in the presence of Umar Ali Shaikh, Chief Executive Officer, Atos Solutions & Systems Pvt Ltd and Member of Parliament (Rajya Sabha) and Chancellor Chandigarh University Satnam Singh Sandhu among other dignitaries.The
More news about: Chandigarh University
Jan 21, 2026, 09:05 ET Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025
TechnologySEATTLE, Jan. 21, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical
More news about: Atossa Therapeutics Inc
Jan 16, 2026, 16:40 ET Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
DesignationSEATTLE, Jan. 16, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical
More news about: Atossa Therapeutics Inc
Jan 16, 2026, 08:14 ET AMTD, proprietária do The Art Newspaper, inicia processo judicial contra INNA BAZHENOVA e GLEB IBRAGIMOV por intimidação, falsidade maliciosa, quebra de confiança e perdas e danos consequentes
disso, o AMTD Group deseja reiterar a sua persistência e dedicação em garantir que a justiça e a equidade prevaleçam contra todos e quaisquer autores de atos maliciosos e intimidatórios contra o AMTD Group e as suas empresas e indivíduos relacionados, e em obter todas as reparações e sanções possíveis contra
More news about: AMTD Digital Inc.; AMTD IDEA Group; The Generation Essentials Group
Jan 06, 2026, 08:15 ET Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer
SEATTLE, Jan. 6, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing innovative medicines for unmet medical needs, today announced that the U.S. Food and Drug Administration
More news about: Atossa Therapeutics Inc
Dec 29, 2025, 06:20 ET Quantum Computing in Financial Services Market Set to Reach USD 6.3 Billion by 2032 as Banks Move from Experimentation to Quantum Advantage | DataM Intelligence
Technology Leaders Shaping Quantum FinanceThe major global players in the market include ABB, Amazon Web Services (AWS), Inc., Aricent, Inc., Atos, Cisco Systems, Inc., General Electric Company, Hewlett Packard Enterprise Development, Honeywell International Inc., Huawei Technologies Co., Ltd.,
More news about: DataM Intelligence 4 Market Research LLP
Dec 18, 2025, 09:00 ET Claroty and Mission IT Partner to Secure U.S. Critical Infrastructure, Accelerate Entrance into U.S. Intelligence Community
technical personnel with high-level security clearances and rigorous training in Claroty's technology. Details of these Mission IT-led deployments and ATOs include:Securing a Military Missile Defense Control System: Mission IT deployed Claroty CTD to perform a full asset discovery,
More news about: Claroty
Dec 17, 2025, 08:15 ET Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category
SettingsSEATTLE, Dec. 17, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical
More news about: Atossa Therapeutics Inc
Dec 15, 2025, 08:00 ET Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium
SEATTLE, Dec. 15, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas
More news about: Atossa Therapeutics Inc
Dec 12, 2025, 17:09 ET Stoltmann Law Offices Wins A Second Arbitration Award Against Coinbase for a Victim of Fraud
information it was duty-bound to protect", concluding that Coinbase's "poor decision making was the catalyst for all the social engineering ATOs which ensued." The arbitration award comes after three days of hearings, prehearing briefs on the law, and post-hearing briefing. The Arbitrator determined
More news about: Stoltmann Law Offices
Dec 11, 2025, 08:00 ET Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy
approvalSEATTLE, Dec. 11, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical
More news about: Atossa Therapeutics Inc
Dec 09, 2025, 09:03 ET Appdome Introduces the First Agentic AI SecOps Agent for Mobile Fraud & Cyber Threats
and skill gaps, simultaneously learn from and evaluate the threat data from the mobile business, and use that knowledge to stop fraud, ATOs, API threats, and more in real time."Making Sense of the Mobile Threat SurfaceMobile teams struggle to understand the dizzying array
More news about: Appdome
Dec 09, 2025, 08:00 ET Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen
conditionsSEATTLE, Dec. 9, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies in areas of significant unmet need in breast
More news about: Atossa Therapeutics Inc
Dec 05, 2025, 10:50 ET Life Sciences BPO Market is expected to generate a revenue of USD 481.8 Billion by 2032, Globally, at 7.50% CAGR: Verified Market Research®
Charles River Laboratories, Parexel International Corporation, PPD (Pharmaceutical Product Development), Covance (a Labcorp company), Syneos Health, Atos SE, Catalent Inc., Wuxi AppTec, Medpace.Life Sciences BPO Market Segment AnalysisBased on the research, Verified Market
More news about: Verified Market Research
Dec 04, 2025, 08:00 ET Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum
settingsSEATTLE, Dec. 4, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming breast cancer treatment and prevention, announced the
More news about: Atossa Therapeutics Inc
Dec 02, 2025, 08:00 ET Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma
2025 /PRNewswire/ -- Insilico Medicine ("Insilico"), a global leader in AI-powered drug discovery, and Atossa Therapeutics ("Atossa") (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel treatments for breast cancer and other serious conditions, announce the publication of
More news about: Atossa Therapeutics Inc
Dec 01, 2025, 14:18 ET Quantum Computing-As-A-Service (QCaaS) Market to Reach USD 18,598.33 million by 2032 at 33.88% CAGR - Credence Research
Quantum LaboratoryIonQ, Inc.Quantum Circuits Inc.Xanadu Quantum TechnologiesCambridge Quantum Computing Ltd.Atos SEFujitsu LimitedToshiba CorporationHewlett Packard Enterprise (HPE)Amazon Web Services (AWS)QxBranch1QBit
More news about: Credence Research Inc.
Nov 26, 2025, 12:12 ET A o9 Solutions entrou com uma denúncia de apropriação indevida de segredos comerciais contra a SAP e ex-executivos da o9 em um tribunal distrital dos EUA
marketing, vendas, roteiro de negócios e outros tipos de materiais confidenciais e de segredos comerciais. A denúncia alega que, ao mesmo tempo que esses atos ocorriam, com o benefício do conhecimento comercial confidencial da o9, a SAP começou a comercializar e vender tecnologias e serviços que continham
More news about: o9 Solutions Inc.
Nov 19, 2025, 07:29 ET Vantage Foundation apoia a Kechara Soup Kitchen em iniciativa de ajuda alimentar comunitária em Kuala Lumpur
pelas comunidades vulneráveis em Kuala Lumpur", disse Steven Xie, Diretor Executivo da Vantage Foundation. "Foi um lembrete humilde de que pequenos atos de serviço podem gerar um grande impacto quando direcionados àqueles que mais precisam." Vantage Foundation
More news about: Vantage Foundation
Nov 17, 2025, 16:10 ET Knox Systems Now Available on Google Cloud Marketplace - Delivering a 90-Day Path to FedRAMP for GCP SaaS Vendors
cloud environment directly to Google Cloud customers. Knox has operated Adobe's Federal Cloud for 10+ years and holds 15 active ATOs across agencies including the Department of Homeland Security, the Treasury Department, NIH, FEMA, and the U.S. Marines. Knox is now listed across
More news about: Knox Systems, Inc
Nov 17, 2025, 09:07 ET Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation
SEATTLE, Nov. 17, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, announces a growing body of scientific
More news about: Atossa Therapeutics Inc
Nov 12, 2025, 14:01 ET O 8º Festival Internacional de Circo da China celebra uma semana de apresentações de classe mundial em Hengqin Chimelong
de apresentações tecnicamente realizadas e bem coordenadas no festival deste ano, proporcionando uma experiência coesa e memorável ao público. Esses atos deslumbrantes de todo o mundo são uma prova do intercâmbio dinâmico entre as artes circenses chinesas e internacionais em Hengqin. Eles representam
More news about: Chimelong Group
Nov 12, 2025, 08:15 ET Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
SEATTLE, Nov. 12, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical
More news about: Atossa Therapeutics Inc
Nov 06, 2025, 08:00 ET Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium
SEATTLE, Nov. 6, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, announces that four abstracts featuring
More news about: Atossa Therapeutics Inc
Oct 29, 2025, 10:01 ET Application Modernization Services Market worth $51.45 billion by 2031 - Report by MarketsandMarkets™
the Application Modernization Services Market are Oracle (US), IBM (US), Microsoft (US), AWS (US), HCL Technologies (India), Accenture (Ireland), ATOS SE (France), Capgemini (France), Cognizant (US), Tata Consultancy Services (India), Aspire Systems (India), NTT Data Group Corporation (Japan), Infosys
More news about: MarketsandMarkets